NASDAQ · Biotechnology · USD

Aardvark Therapeutics, Inc. (AARD) Stock Analysis

Aardvark Therapeutics, Inc. (AARD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

AARD

$5.38

−$0.35 (−6.11%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AARD with… →

AARD Key Statistics

As of Sep 4, 2026

Trading

Open: $5.72
Previous Close: $5.73
Day's Range: 5.15–5.99
52-Week Range: 3.35–17.94
Volume: 257.80K

Valuation

Market Cap: $117.74M
P/E Ratio: unprofitable
EPS (ttm): −3.02

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$57.59M
Profit margin: 0.00%
Shares Outstanding: 21.88M
1-Year Return: −36.63%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 249.47K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AARD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	−59.01%
2025 (partial year)	−8.28%

As of September 4, 2026.

AARD Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$57.59M	—
2024	$0.00	−$20.59M	—
2023	$0.00	−$7.21M	—
2022	$0.00	−$13.56M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$62.73M	−$57.59M	—
2024	$0.00	—	−$22.67M	−$20.59M	—
2023	$0.00	—	−$6.65M	−$7.21M	—
2022	$0.00	—	−$10.87M	−$13.56M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AARD Valuation vs Biotechnology Median

Median of 656 stocks

Metric	AARD	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Aardvark Therapeutics, Inc. (AARD) carries a market capitalisation of $117.74M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 28 employees.

The 52-week range on file runs from $3.35 to $17.94. The most recent close on file for AARD is $5.38, dated September 4, 2026. That is −$0.35 (−6.11%) against the previous close. The latest close sits 60.6% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $57.59M. Profit margin runs at 0%. Trailing earnings per share are −3.02.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is −36.63%. The stored price history starts on February 13, 2025, and the total return since then is −62.40%. Annualized volatility over the trailing 1 year is 127.84%.

Growth & Income

No dividend is on file for AARD.

So far in 2026 the price is −59.01%.

Peer Comparison

Aardvark Therapeutics, Inc. (AARD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Aardvark Therapeutics, Inc.	AARD	$117.74M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Aardvark Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Visit website →